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Abstract
Background: UroVysion fluorescence in situ hybridization (uFISH) was reported to have superior sensitivity to urine
cytology. However uFISH studies are limited by varying definitions of what is considered a positive result, absence
of histopathology and small sample size. The aim of our study was to better determine the performance characteristics
of uFISH and urine cytology by overcoming some of the deficiencies of the current literature.
Methods: Intraoperative bladder wash cytology and uFISH were collected prospectively on all patients. Strict
definitions for positivity of uFISH and cytology were determined before initiating the study. A re-review of
false-negative uFISH specimens was performed to analyze potential sources of error. Sixteen bladder tumors
embedded in paraffin were analyzed by uFISH and compared with the result in the urine.
Results: One hundred and twenty-nine specimens were analyzed. Sensitivity was 67% and 69% (p = 0.54);
specificity was 72% and 76% (p = 1.0), for uFISH and cytology, respectively. Thirty-two false negative uFISH
samples were re-reviewed. Low grade tumors often showed cells with abnormal morphology and patchy DAPI
staining but diploid chromosomal counts and a few high grade tumors had tetraploid counts but less than
needed to interpret uFISH as positive. uFISH study of the tumors revealed three categories; positive in both
tumor and urine (9), negative in both tumor and urine (5) and positive in tumor but negative in urine (2).
Conclusion: In a pathologically-confirmed analysis of bladder washed urine specimens, uFISH does not outperform
urine cytology in cancer detection.
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Background
UroVysion fluorescence in situ hybridization (uFISH) is a
multitarget, multicolor FISH assay that has been developed
for the detection of urothelial carcinoma in the urine [1].
The assay is mostly used in the surveillance of patients
with a history of bladder cancer [2–4]. Numerous studies
have compared the performance characteristics (sensitivity
and specificity) of uFISH to urinary cytology [5–12]. A
recent meta-analysis of the published literature on uFISH
reported superior sensitivity and comparable specificity
when compared to cytology [13].
uFISH is reported dichotomously (either positive or
negative) based on criteria that include not only
chromosomal changes but cell morphology. Despite the
stringency of test reporting as either positive or negative,
difficulty of interpretation of chromosomal and morpho-
logic changes does exist, potentially influencing the use-
fulness of the test in cancer detection. Limitations of
previous publications on uFISH include varying defini-
tions of what is considered a positive result, lack of
histopathology and small sample size [14–19]. Also the
likelihood a given bladder cancer may not have the
chromosomal alterations measured by uFISH and thus
not capable of being detected by the test is not entirely
known.
Similar to uFISH, urinary cytology is reported as positive
or negative however additional terminology in reporting
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cytology specimens includes suspicious and atypical.
The clinical significance of an atypical cytology has been
debated and whether an atypical cytology is considered
positive or negative influences the sensitivity of urine
cytology in bladder cancer detection. A recent large scale
study provides further evidence that classifying an atypical
cytology as negative has little influence of the sensitivity of
cancer detection [20].
The aim of our study was to better determine the per-
formance characteristics of uFISH and urine cytology by




Institutional review board approval was obtained for an
institutional tissue- and body fluid banking protocol.
Patients were consented to allow for collection of urine
specimens and fresh frozen and formalin-fixed paraffin
embedded tumor tissue for research purposes, if not
clinically needed, in a prospective manner on all patients
undergoing transurethral resection of bladder tumor
(TURBT) or radical cystectomy (RC). A total of 129
urine specimens were included in the study. Following
induction of anesthesia and immediately prior to the
surgical procedure, two 60 ml bladder-washed aliquots
of urine were obtained via a rigid cystoscope for TURBT
or urethral catheter for RC. The two aliquots were ran-
domly assigned for urine cytology or uFISH analysis.
In addition, 16 formalin fixed paraffin embedded (FFPE)
bladder tumor specimens and 4 normal bladder urothelial
samples were analyzed by uFISH. A representative area
containing ≥80% tumor cells was selected for uFISH
testing on each FFPE slide. All tumors evaluated in this
study represented primary bladder cancers.
uFISH and cytology
All cytology specimens were analyzed by two ctyopatholo-
gists each with over 10 years of experience in urine
cytology. Samples for conventional urine cytology were
centrifuged and obtained by the Cytospin method. The
slides were then stained by the standard Papanicolaou
method. All uFISH specimens were processed according
to the manufacturer’s protocol by one cytogenetic techni-
cian and analyzed by one cytogeneticist with many years
of experience in cytogenetics and cell morphology. The
pathologists and cytogeneticist had no prior knowledge of
this study. Tissue samples were evaluated by standard
institutional protocol.
uFISH positivity in the bladder washings was deter-
mined by the criteria as listed in the package insert after
all cells in a 15 mm diameter site were evaluated. Four
or more abnormal cells that had chromosomal gain for
at least two of chromosomes 3, 7 or 17 or ≥12 cells with
homozygous loss of 9p21 or samples with ≥10 tetraploid
cells with normal morphology were considered positive.
A previous unpublished institutional effort determined
that urothelial cancer was proven histologically when
the cytology was reported as positive in 9/9 (100%), sus-
picious in 8/9 (89%) and atypical in 1/13 (7%) patients.
Importantly all patients with a negative cytology all had
a normal cystoscopy. Therefore for the purpose of this
study a positive or suspicious cytology was considered
positive and an atypical and negative cytology was con-
sidered negative. These definitions were generated prior
to data analysis.
All TURBT were performed in a standardized manner
that included an initial assessment of the entire bladder
and prostatic urothelium and a pre- and post-resection
exam under anesthesia. All areas of visible tumor as well as
sites of previous resection were resected in their entirety.
Random bladder and/or prostate urothelial biopsies were
frequently performed. Upper urinary tract evaluation by
urography was always performed and the presence of
upper urinary tract carcinomas was excluded. Radical
cystectomy was performed as previously reported [21].
Final histopathology from the operative specimen was
considered the standard to which uFISH and cytology
were compared.
At the completion of the study the cytogeneticist was
unblinded and a post-hoc analysis of false-positive and
false-negative uFISH was conducted. Information re-
garding cellularity, morphology, DAPI (4,6-Diamidino-2-
Phenylindole) staining, and aneuploidy of the uFISH
chromosomes that was not presented in the initial report
was collected. All false-negative uFISH slides were re-run
with residual urine from the original aliquot to ensure
quality control.
uFISH in the tumors
For FISH, 5-μm paraffin sections were placed in xylene
for 30 (3 × 10) minutes followed by dehydration in 100%
ethanol for 10 (2 × 5) minutes. Prior to hybridization,
the slides were treated with Paraffin Pretreatment
Reagent Kit (Abbott Molecular Inc., Des Plaines, IL,
USA, Cat. # 32–801,200) and dehydrated in 70%, 85%,
and 100% alcohol solutions for 5 min each. FISH was
performed using UroVysion probe (Abbott Molecular,
Des Plaines, IL). Denaturation of the DNA was carried
out at 75 °C for 10 min (probe mixture) or 5 min
(slides). The probe mixture was applied to the slides and
hybridized overnight in a moist chamber at 37 °C. The
post-hybridization washes were performed as described
in ‘LSI procedure’ (Abbott Molecular Inc., Des Plaines,
IL, USA). Slides were counterstained with 125 ng/ml
DAPI in antifade. A minimum of 25 tumor cells were
analyzed for copy number changes of chromosomes 3, 7,
17 and 9p21 [22]. If no abnormalities were detected, the
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remaining cells were counted until a sufficient number
of cells with chromosomal abnormalities were found, or
until 200 cells were evaluated, or the whole specimen
was analysed. A positive result was the presence of ≥4
cells with gains of two or more of chromosomes 3, 7
and 17. In the case of chromosome 9p21, a positive re-
sult was considered when ≥12 cells showed absence of
9p21 signals.
Statistics
Data was collected and compiled using SPSS v.15.0.
Statistical analyses were performed using McNemar’s
test for comparisons between uFISH and cytology and
the chi-squared test for other comparisons. All p-values
are two-sided.
Results
One hundred and twenty-nine urine samples were in-
cluded in the study and collected at the time of TURBT
(n = 94) or at RC (n = 35). Baseline characteristics of
the study population and TURBT or RC pathology are
listed in Table 1.
The indication for TURBT was suspicious cystoscopic
findings for cancer in 48 (51%) patients on surveillance
for a history of non-muscle invasive bladder cancer
(NMIBC), repeat TURBT within 6 weeks of the initial
TURBT for confirming completeness of tumor resection
in 38 (40%) patients [23] and a positive urinary cytology
with normal cystoscopic findings in 8 (9%) patients.
Eighty percent of the TURBTs were performed on patients
who had previously been diagnosed with bladder cancer
and 73 (78%) specimens collected by TURBT identified
the presence of cancer. All of the RC specimens had
evidence for cancer except one specimen. A histologic
diagnosis of cancer was present in 101 specimens (78%).
Urine cytologies were reported as positive, consistent
or suspicious for carcinoma or reported as negative,
atypical or the presence of papillary clusters without
fibrovascular cores. For the purpose of this study the
definition of a positive or negative cytology is given in
Table 2 along with the relative frequency of the cytologic
descriptions. The interpretation of uFISH is described in
the methods.
The overall performance of uFISH and cytology is
shown in Table 3. uFISH was positive in 73 (56%) col-
lected specimens and cytology was positive in 76 (59%).
Overall sensitivity was 67% and 69% for uFISH and
cytology (p = 0.54) and specificity was 72% and 76% for
uFISH and cytology (p = 1.0), respectively. Sensitivity of
the tests by tumor grade and stage is given in Table 4.
Each of the sensitivity comparisons between uFISH and
cytology was not statistically significant (p > 0.05). Simi-
larly, no significant differences in sensitivity between
uFISH and cytology were found when restricting the
analysis to TURBT or RC procedures.
The grade and stage of the tumors of the 32 false-
negative uFISH specimens and 31 false negative cytologies
are also presented in Table 4. False negative results were
noted in both low and high grade tumors as well as
tumors of all pathologic stages, including carcinoma in
situ. Specific analysis of the low grade Ta tumors identi-
fied a false negative result in 9 uFISH and 9 cytology
specimens. Re-review of the uFISH slides from the false
negative specimens often showed the presence of cells
with abnormal morphology and patchy DAPI staining but
diploid chromosomal counts and enough cellular material
to interpret the test result as negative. In addition, of
the 32 false-negative uFISH specimens, nine were from
RC specimens. Each of the 9 RC specimens had signifi-
cant papillary tumor burden on gross and microscopic
Table 1 Patient and tumor characteristics
Mean Age (yrs) 68
Male:Female 102:27
TURBT 94 (73%)
Radical Cystectomy 35 (27%)
Indication for TURBT:
Cystoscopic Abnormality: 48 (51%)
New diagnosis 19
Recurrence 29
Completion of initial TURBT 38 (40%)












Any CIS 47 (36%)
Table 2 Nomenclature for classification of urinary cytology reports
Positive cytology (n = 76)
Urothelial Carcinoma/Positive for malignancy (40)
Severely atypical cells consistent with high grade urothelial carcinoma (6)
Suspicious for carcinoma (30)
Negative cytology (n = 53)
No evidence of carcinoma/malignancy (32)
Urothelial atypia (18)
Papillary clusters without fibrovascular cores (3)
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pathology and final pathologic stage was pT2 (4), pT3
(4) and pT4 (1). Some of these same RC specimens also
had the presence of carcinoma in situ (CIS). Re-review
of the uFISH slides from these 9 specimens demon-
strated three tumors with tetraploid counts but less
than the number needed to interpret FISH as positive.
Analysis of the complementarity of the two tests was
performed by examining the number of false-negatives
from one test that were detected by the other. Fourteen
(44%) false-negative uFISH had positive cytologies, while
10 (36%) false-negative cytologies had positive uFISH.
Thus 64% of tumors missed by cytology would also have
been missed by a concomitant uFISH. The sensitivity
when either uFISH or cytology is considered positive
was 82%, while the specificity of such a definition was
59%. If uFISH and cytology are both positive concurrently,
the sensitivity decreases to 57% while specificity is 93%.
Review of the longterm clinical history of the 7 false-
positive uFISH specimens revealed that three patients later
underwent RC and another patient was recommended to
undergo a RC for high risk of disease progression. Each of
these four patients had muscle invasive disease with or
without CIS when they recurred. Two additional patients
developed upper urinary tract urothelial cancer and under-
went a nephroureterectomy. The remaining patient has
not recurred in more than two years of follow-up.
Four normal FFPE bladder urothelial samples and 16
FFPE tumor samples were evaluated by FISH to determine
how often the chromosomal changes quantitated by the
UroVysion FISH assay were present in the tumor. About
20% of the low and high grade tumors and 20% of the
NMIBC and MIBC included in the study were chosen to
measure UroVysion FISH positivity. All four normal
samples analyzed were uFISH negative because of normal
copy number counts. The uFISH data for both the tumor
and the corresponding urine specimen are presented in
Table 5. Importantly 5 of 16 tumors (31%) were uFISH
negative and the corresponding urine sample for these
tumors was also uFISH negative. The uFISH negative
tumors included tumors of low and high grade as well as
superficial and invasive disease. Also two tumors deter-
mined to be uFISH positive had a corresponding uFISH
negative urine sample, including one high grade tumor.
Discussion
The main reported advantage of uFISH is increased
sensitivity of cancer detection when compared to urine
cytology, especially in high grade tumors [18, 24]. How-
ever, false-negative results still occur and may be due to
failure of tumor detection at cystoscopy or an “anticipatory
positive” UroVysion FISH [25]. In addition, in order for
uFISH to identify the presence of a cancer it is necessary
the cancer has gains of at least two of chromosomes 3, 7
or 17 in at least four or loss of 9p21 in at least twelve, mor-
phologically abnormal cells, in accordance with the FDA
approval of the uFISH assay [1, 5]. And in fact, our study
suggests not all bladder cancers have the chromosomal al-
terations detected by uFISH.
In addition, the uFISH assay is also associated with
false positive results. One explanation for false positive
results is the presence of tetraploidy in the uFISH assay
that may reflect normal cell division or a proliferative re-
sponse of the bladder epithelium to an inflammatory insult
and not a cancerous process. Zellweger et al. determined
the number of uFISH false positives can be reduced by
establishing the presence of tetraploidy in at least 10
Table 3 uFISH and cytology performance by stage
Pathological stage Negative uFISH Positive uFISH Negative cytology Positive cytology
No Tumor 28 21 7 22 6
Tumor 101a 32 66 31 70
• Non-muscle invasive bladder cancer (≤ pT1) 66a 23 40 22 44
• Muscle invasive bladder cancer (≥ pT2) 35 9 26 9 26
aThree samples were not analyzed by uFISH due to lack of enough cellular material
Table 4 Sensitivity of uFISH and cytology by grade and stage
na uFISH sensitivity (%) Cytology sensitivity (%) p-value* False negative uFISH (n = 32) False negative cytology (n = 31)
Low Grade 14 25% 36% 0.63 9 9
High Grade 87 73% 75% 0.82 23 22
Any CIS 47 79% 83% 0.73 10 8
CIS alone 16 75% 81% 1.0 4 3
≤pT1 66a 63% 67% 0.45 23 22
≥ pT2 35 74% 74% 1.0 9 9
aThree samples were not analyzed by uFISH due to lack of enough cellular material
*Comparison of uFISH and Cytology sensitivity
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morphologically abnormal cells as this is more reflective of
the presence of cancer [26]. The importance of defining
the number of cells with tetraploidy in the uFISH assay
was further supported by the work of Kipp et al. [27].
Patients in both studies with a normal cystoscopy and a
positive uFISH result based on defining teteraploidy in at
least 10 cells were more likely to be diagnosed with cancer
at the time of the original bladder biopsy or subsequent
bladder biopsy thus improving upon both the sensitivity
and specificity of the uFISH assay. Based on these publica-
tions our institution and others include tetraploidy in at
least 10 morphologically abnormal cells in the definition of
a positive uFISH result, in addition to the FDA approved
criteria [27].
Our discussion mostly focuses on the false negative re-
sult and sensitivity of the uFISH assay. An extensive re-
view by Jones of nine uFISH studies reported a
sensitivity of 96% in CIS lesions (44 specimens) and 94%
in 87 invasive tumor specimens [28]. Promotional litera-
ture for the uFISH test kit reports a “near 100% sensitiv-
ity for dangerous high grade lesions” [17]. However our
study findings are not consistent with these reports as
we found a sensitivity of 79% in 47 CIS lesions and 74%
in 35 invasive lesions. Moreover, our study findings are
similar to other studies that indicate the performance of
traditional urine cytology is similar to uFISH in bladder
cancer detection [29, 30].
Why do our results of uFISH sensitivity differ from
some other reports? Our study attempted to reduce the
limitations of previous publications that may have in-
cluded varying definitions of what is considered a posi-
tive uFISH result, lack of histopathology, heterogeneous
patient population and small sample size. In our study
all patients were evaluated in the operating room for
presumed bladder cancer and had concurrent bladder
washed urine samples thus increasing the cellularity of
the specimen and histopathology for comparison. Only
14% of patients had low-grade tumors and 27% of speci-
mens were acquired at the time of radical cystectomy for
invasive disease. Therefore the patients included in the
study presumably have a high likelihood of a positive
uFISH and are more representative of the true performance
characteristics of uFISH.
After the study concluded we validated our uFISH
sensitivity analysis by re-evaluating the false negative
cases. To this end a single experienced cytogenetic tech-
nician repeated the analysis of all false-negative speci-
mens from stored residual urine and compared the
result to the originally processed urine sample for the
same patient. All false negative uFISH urine samples
were confirmed to be negative on repeat evaluation.
Importantly several samples contained morphologically
abnormal cells and tetraploidy in less than 10 cells of
the targeted probes and absence of the FDA approved
criteria for a positive test result. We also recognized the
urine samples obtained from most low grade tumors
were comprised of morphologically abnormal cells with
patchy DAPI nuclear staining but had normal diploid
counts of the Urovysion markers. Therefore it is possible
that bladder tumors with a negative urine uFISH do
not have the chromosomal alterations that the uFISH
test is detecting.
To investigate this possibility we directly performed
uFISH analysis of 16 bladder tumors of varying grades
and stages. Our findings determined that about 30% of
bladder tumors do not have aneuploidy of chromosomes
3, 7, 17 or 9p21 and may explain some of the uFISH
false negatives in our evaluation of the urine samples in
not only high grade tumors but also low grade tumors.
However, our study determined that all tumors, with
two exceptions, with the uFISH chromosomal alterations
can be detected in the corresponding urine sample. The
findings of our study suggest the need for a more com-
prehensive cytogenetic evaluation of bladder cancer is
needed to improve FISH based testing. The benefit of
using complementary molecular tests in the urine such
as loss of heterozygosity, nuclear matrix protein 22
(NMP22) and array comparative genomic hybridization
(array CGH) has been shown in the literature [31–33].
Therefore, as the cost of next-generation sequencing,
microarray-based CGH and other global approaches
decreases and becomes more clinically applicable these
technologies should be studied alone or as a comple-
ment to uFISH to improve bladder cancer detection.
As a final comment, in our study the sensitivity of urine
cytology was much higher in high grade tumors when
compared to low grade tumors. This was an expected re-
sult however we did note a higher sensitivity (36%) for
urine cytology in low grade tumors in our study when
compared to prior publications. The likely explanation of
Table 5 uFISH results in formalin-fixed paraffin embedded (FFPE) tumors and corresponding urine samples








Low Grade 2 1 2 1 0
High Grade 14 4 5 10 9
≤pT1 9 1 2 8 7
≥ pT2 7 4 5 3 2
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a positive cytology in the six patients with low grade
tumors in this study is the fact that five of the patients
were defined as intermediate risk tumors characterized by
multifocality and tumors were greater than 3 cm in size.
The collection of the urine samples by washing or barbo-
tage is known to increase cellular yield of the sample.
Therefore when the burden of tumor is high, even in the
context of low grade tumors, it is more likely a positive
cytology will be obtained when the specimen is collected
by barbotage compared to a voided sample.
Our study design is clearly limited by its lack of clinical
applicability. However, the study was purposely designed
to advance the current state of knowledge of uFISH by de-
termining its true performance characteristics as it is used
today and to recognize opportunities for improvement.
The study provides valuable new insights on improving
FISH based assays and the need to better standardize
definitions of reporting a positive result.
Conclusions
In a prospective, pathologically-confirmed analysis of
intraoperative bladder washed urine specimens, Urovysion
FISH does not outperform traditional urine cytology in
either sensitivity or specificity.
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